Visfatin/PBEF/Nampt: A new cardiovascular target?

32Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

Abstract

In the last years, a growing interest has emerged toward understanding the role of adipocytokines in the development of cardio-metabolic complications. Five years ago, visfatin/PBEF/Nampt was identified as a novel adipocytokine. In the context of metabolic disorders, extracellular visfatin/PBEF/Nampt was initially claimed as a potentially beneficial molecule due to its insulin-mimetic and glucose-lowering properties. Nevertheless, growing evidence has since then unveiled that visfatin/PBEF/Nampt may rather be a biomarker of inflammation and endothelial damage, and also a direct regulator of the cardiovascular system that modulates cell proliferation and survival, extracellular matrix, vascular reactivity, and inflammation. On one side, the blockade of the deleterious cardiovascular actions of visfatin/PBEF/Nampt is being regarded as a potential approach to prevent and treat, not only cardio-metabolic complications, but also other pathologies implying excessive angiogenesis. Conversely, the administration of visfatin/PBEF/Nampt has shown beneficial effects in different ischemic conditions. Further research is required to evaluate the real value of visfatin/PBEF/Nampt as a pharmacological target. © 2010 Peiró, Romacho, Carraro and Sánchez-Ferrer.

Cite

CITATION STYLE

APA

Peiró, C., Romacho, T., Carraro, R., & Sánchez-Ferrer, C. F. (2010). Visfatin/PBEF/Nampt: A new cardiovascular target? Frontiers in Pharmacology, 1 NOV. https://doi.org/10.3389/fphar.2010.00135

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free